PDF(Pubmed)
Abstract：
UNASSIGNED: The genetic nature of cancer provides the rationale to support the need for molecular diagnosis and patient selection for individualised antineoplastic treatments that are the best in both tolerability and efficacy for each cancer patient, including non-small cell lung cancer (NSCLC) patients. Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations represent the prevalent oncogenic driver in NSCLC, being detected in roughly one-third of cases and KRAS G12C is the most frequent mutation found in approximately 13% of patients.
UNASSIGNED: This paper gives an overview of the numerous scientific efforts in recent decades aimed at KRAS inhibition.
UNASSIGNED: Sotorasib is the first approved KRAS G12C inhibitor that has been shown to provide a durable clinical benefit in patients with pre-treated NSCLC with KRAS G12C mutation. Together with the development of new targeted drugs, the development of strategies to control resistance mechanisms is one of the major drivers of research that is exploring the use of KRAS inhibitors not only alone, but also in combination with other targeted therapies, chemotherapy and immunotherapy.
UNASSIGNED: This review will describe the major therapeutic developments in KRAS mutation-dependent NSCLC and will analyse future perspectives to maximise benefits for this group of patients.
UNASSIGNED: This paper gives an overview of the numerous scientific efforts in recent decades aimed at KRAS inhibition.
UNASSIGNED: Sotorasib is the first approved KRAS G12C inhibitor that has been shown to provide a durable clinical benefit in patients with pre-treated NSCLC with KRAS G12C mutation. Together with the development of new targeted drugs, the development of strategies to control resistance mechanisms is one of the major drivers of research that is exploring the use of KRAS inhibitors not only alone, but also in combination with other targeted therapies, chemotherapy and immunotherapy.
UNASSIGNED: This review will describe the major therapeutic developments in KRAS mutation-dependent NSCLC and will analyse future perspectives to maximise benefits for this group of patients.
摘要：
癌症的遗传性质为支持分子诊断和患者选择个体化抗肿瘤治疗的必要性提供了理论基础，这些个体化抗肿瘤治疗对每位癌症患者的耐受性和疗效均最佳。包括非小细胞肺癌（NSCLC）患者。Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）突变代表了NSCLC中普遍的致癌驱动因素，在大约三分之一的病例中检测到KRASG12C是在大约13%的患者中发现的最常见的突变。
■本文概述了近几十年来针对KRAS抑制的众多科学努力。
■Sotorasib是第一个被批准的KRASG12C抑制剂，已被证明可为患有KRASG12C突变的前治疗NSCLC患者提供持久的临床益处。随着新的靶向药物的开发，制定控制抗性机制的策略是探索不仅单独使用KRAS抑制剂的研究的主要驱动因素之一，而且还与其他靶向治疗相结合，化疗和免疫疗法。
■这篇综述将描述KRAS突变依赖性非小细胞肺癌的主要治疗进展，并将分析未来的观点，以最大限度地为这组患者带来益处。
■本文概述了近几十年来针对KRAS抑制的众多科学努力。
■Sotorasib是第一个被批准的KRASG12C抑制剂，已被证明可为患有KRASG12C突变的前治疗NSCLC患者提供持久的临床益处。随着新的靶向药物的开发，制定控制抗性机制的策略是探索不仅单独使用KRAS抑制剂的研究的主要驱动因素之一，而且还与其他靶向治疗相结合，化疗和免疫疗法。
■这篇综述将描述KRAS突变依赖性非小细胞肺癌的主要治疗进展，并将分析未来的观点，以最大限度地为这组患者带来益处。
